FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Valeant Pharmaceuticals North America Lodrane D Recall

Lodrane D (Brompheniramine maleate 4 mg and Pseudoephedrine HCl 60 mg) Capsules, 60-cou…

Valeant Pharmaceuticals North America LLC · Bridgewater, NJ

Risk level
Class III
Reported by FDA
Jun 22, 2016
Recall ID
D-1032-2016
Check your lot numberHow we source this data

Summary

Valeant Pharmaceuticals North America recalled Lodrane D starting May 23, 2016. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-1032-2016 on Jun 22, 2016. Reason: Labeling: Not Elsewhere Classified: correctly labeled bottles were packaged in cartons that were mislabeled with an incorrect active ingredient, phenylephrine rather than pseudoephedrine, on the carton face and carton top. Status: Terminated.

Why it was recalled

Labeling: Not Elsewhere Classified: correctly labeled bottles were packaged in cartons that were mislabeled with an incorrect active ingredient, phenylephrine rather than pseudoephedrine, on the carton face and carton top.

Product description

Lodrane D (Brompheniramine maleate 4 mg and Pseudoephedrine HCl 60 mg) Capsules, 60-count bottles, Distributed by: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807, UPC 0 00950 86006 8.

Lot numbers, UPCs & expiration codes

Lot #'s P0230-022R, P0230-023R, Exp 06/17

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1032-2016
Classification
Class III
Status
Terminated
Recall initiated
May 23, 2016
FDA report date
Jun 22, 2016
Quantity
3827 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Valeant Pharmaceuticals North America LLC

Original FDA data

Every field from FDA enforcement report D-1032-2016, exactly as published.

Show all FDA fields
City
Bridgewater
State
NJ
Status
Terminated
Country
United States
Event ID
74223
Address
400 Somerset Corporate Blvd
Code information
Lot #'s P0230-022R, P0230-023R, Exp 06/17
Postal code
08807-2867
Report date
Jun 22, 2016
Product type
Drugs
Recall number
D-1032-2016
Classification
Class III
Recalling firm
Valeant Pharmaceuticals North America LLC
Product quantity
3827 bottles
Termination date
Sep 12, 2017
Reason for recall
Labeling: Not Elsewhere Classified: correctly labeled bottles were packaged in cartons that were mislabeled with an incorrect active ingredient, phenylephrine rather than pseudoephedrine, on the carton face and carton top.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Lodrane D (Brompheniramine maleate 4 mg and Pseudoephedrine HCl 60 mg) Capsules, 60-count bottles, Distributed by: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807, UPC 0 00950 86006 8.
Distribution pattern
Nationwide
Recall initiation date
May 23, 2016
Initial firm notification
Letter
Center classification date
Jun 15, 2016

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1032-2016, published Jun 22, 2016. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls